Study | Chen et al. [24] | Pan et al. [25] |
---|---|---|
Study design | Prospective non-randomized control trial | Prospective randomized control trial |
No. of mother | TDF (N = 92), Control (N = 56) | TDF (N = 97), Control (N = 100) |
Intervention | TDF vs. Control | TDF vs. Control |
Time of intervention | 30–32 weeks of gestation | 30-32 weeks of gestation |
Maternal viral load | ≥20,000,000 IU/mL | ≥200,000 IU/mL |
Maternal HBeAg-positive rate | 100% | 100% |
Mother-to-infant transmission rate | TDF (1.54%) vs. Control (10.71%), P = 0.0481* | Intention-to-treat analysis: TDF (5%) vs. Control (18%), P = 0.007** Per-protocol analysis: TDF (0%) vs. Control (7%), P = 0.01 |